DCT

3:26-cv-12849

Takeda Pharma USA Inc v. Zydus Pharma USA Inc

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 3:26-cv-12849, D.N.J., 09/30/2026
  • Venue Allegations: Plaintiff alleges venue is proper in the District of New Jersey based on Defendant Zydus Pharmaceuticals (USA) Inc. having a principal place of business in the district, conducting business in the district, and having previously consented to personal jurisdiction in the district in prior patent litigation.
  • Core Dispute: Plaintiff alleges that Defendant’s submission of an Abbreviated New Drug Application (ANDA) for a generic budesonide oral suspension infringes two patents related to stable corticosteroid compositions and their use in treating eosinophilic esophagitis.
  • Technical Context: The technology concerns pharmaceutical formulations designed to improve the storage stability of corticosteroids like budesonide by using a specific antioxidant system, primarily for oral treatment of inflammatory esophageal conditions.
  • Key Procedural History: This action was initiated under the Hatch-Waxman Act following Defendant’s submission of ANDA No. 221618 with a Paragraph IV certification, which challenges the validity or infringement of the patents-in-suit. The patents are listed in the FDA’s Orange Book for the branded drug EOHILIA®. Defendant provided a notice letter of its ANDA filing to the Plaintiff on August 18, 2026.

Case Timeline

Date Event
2018-01-11 Priority Date for ’064 and ’934 Patents
2022-03-01 U.S. Patent No. 11,260,064 Issued
2023-01-31 U.S. Patent No. 11,564,934 Issued
2026-08-18 Defendant’s Notice Letter Sent to Plaintiff
2026-09-30 Complaint for Patent Infringement Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 11,260,064 - Stable Corticosteroid Compositions (Issued: Mar. 1, 2022)

  • The Invention Explained:
    • Problem Addressed: The patent addresses the problem of oxidative degradation in pharmaceutical compositions containing corticosteroids like budesonide, which can form undesirable impurities such as 21-dehydro budesonide (21-DHB) during storage, compromising the product's stability and shelf life ’064 Patent, col. 1:12-18 The patent also notes the challenge of creating formulations that are palatable and non-allergenic, particularly for pediatric patients ’064 Patent, col. 2:1-6 ’064 Patent, col. 7:59-67
    • The Patented Solution: The invention is a pharmaceutical composition that stabilizes the corticosteroid by including a specific antioxidant system comprising "a combination of ascorbic acid and a pharmaceutically acceptable salt of ascorbate" ’064 Patent, col. 2:59-63 This system is intended to protect the active ingredient from degrading in the presence of oxygen, thereby ensuring the composition remains stable over time ’064 Patent, abstract ’064 Patent, col. 2:46-52
    • Technical Importance: This approach allows for the creation of a stable, liquid oral formulation of budesonide, which is crucial for delivering a consistent and effective dose for treating conditions like eosinophilic esophagitis (EoE), especially in patients who have difficulty with other administration methods ’064 Patent, col. 2:1-6
  • Key Claims at a Glance:
    • The complaint asserts infringement of at least independent claim 1 Compl. ¶41
    • Independent Claim 1 Elements:
      • A pharmaceutical composition comprising budesonide,
      • an antioxidant in an amount of from about 0.05% to about 0.5% w/w of the composition, wherein the antioxidant comprises a combination of ascorbic acid and a pharmaceutically acceptable salt of ascorbate,
      • and a flavoring agent, a sweetener, or a combination thereof,
      • wherein the pharmaceutical composition comprises less than 0.3% impurities formed by oxidative degradation,
      • and wherein the pharmaceutical composition is for oral administration.
    • The complaint reserves the right to assert other claims Compl. ¶40

U.S. Patent No. 11,564,934 - Stable Corticosteroid Compositions (Issued: Jan. 31, 2023)

  • The Invention Explained:
    • Problem Addressed: As a divisional of the ’064 patent, this patent addresses the same technical problem: the need for a stable and palatable oral formulation to treat inflammatory gastrointestinal disorders like EoE ’934 Patent, col. 1:17-27
    • The Patented Solution: The ’934 Patent claims a method of medical treatment using the stable composition. The invention is a method for treating or alleviating the symptoms and inflammation associated with EoE by administering the pharmaceutical composition comprising budesonide and the specific ascorbic acid/ascorbate salt antioxidant system ’934 Patent, abstract ’934 Patent, claim 1
    • Technical Importance: By claiming the specific method of use, the patent provides protection for the therapeutic application of the stable formulation, linking the technical solution of the composition directly to its clinical benefit in treating EoE ’934 Patent, col. 4:1-5
  • Key Claims at a Glance:
    • The complaint asserts infringement of at least independent claim 1 Compl. ¶54
    • Independent Claim 1 Elements:
      • A method of treating, or alleviating the symptoms of and inflammation associated with eosinophilic esophagitis in a subject in need thereof
      • comprising administering to the subject a pharmaceutical composition comprising budesonide,
      • and an antioxidant in an amount of from about 0.05% to about 0.5% w/w of the composition,
      • wherein the antioxidant comprises a combination of ascorbic acid and a pharmaceutically acceptable salt of ascorbate,
      • wherein the pharmaceutical composition comprises less than 0.3% impurities formed by oxidative degradation.
    • The complaint reserves the right to assert other claims Compl. ¶53

III. The Accused Instrumentality

  • Product Identification: The accused instrumentality is "Zydus's ANDA Product," a generic budesonide oral suspension (2 mg/10 mL) for which Zydus has submitted ANDA No. 221618 to the FDA (Compl. ¶¶1, 30).
  • Functionality and Market Context: The complaint alleges that Zydus's ANDA Product is intended to be a generic version of Plaintiff's EOHILIA® drug product Compl. ¶34 EOHILIA® is a corticosteroid indicated for the treatment of eosinophilic esophagitis in patients 11 years of age and older Compl. ¶8 Plaintiff alleges Zydus is "a leading generic pharmaceutical company in the US" and seeks to commercially manufacture and sell its generic product prior to the expiration of the patents-in-suit (Compl. ¶1; Compl. ¶13). No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

The complaint alleges that Zydus's ANDA Product, and its proposed use, will infringe the asserted patents literally or under the doctrine of equivalents Compl. ¶42 Compl. ¶55 The infringement theory for the '934 method patent is based on inducement, alleging Zydus's product labeling will instruct users to perform the patented method Compl. ¶56

’064 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A pharmaceutical composition comprising budesonide... The complaint alleges Zydus's ANDA Product is a budesonide oral suspension. ¶30 col. 7:11-13
an antioxidant in an amount of from about 0.05% to about 0.5% w/w of the composition, wherein the antioxidant comprises a combination of ascorbic acid and a pharmaceutically acceptable salt of ascorbate... The complaint alleges on information and belief that the ANDA Product contains a formulation that meets this element. ¶42 col. 2:59-63
and a flavoring agent, a sweetener, or a combination thereof... The complaint alleges on information and belief that the ANDA Product meets this element. ¶42 col. 7:7-8
wherein the pharmaceutical composition comprises less than 0.3% impurities formed by oxidative degradation... The complaint alleges on information and belief that the ANDA Product meets this stability requirement. ¶42 col. 8:66-67
and wherein the pharmaceutical composition is for oral administration. The complaint identifies the ANDA product as an "oral suspension." ¶30 col. 5:48-49

’934 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A method of treating, or alleviating the symptoms of and inflammation associated with eosinophilic esophagitis in a subject in need thereof... The complaint alleges Zydus's ANDA Product is a generic version of EOHILIA®, which is indicated for EoE, and its labeling will instruct this use. ¶34; ¶56 col. 8:10-15
comprising administering to the subject a pharmaceutical composition comprising budesonide, and an antioxidant...wherein the antioxidant comprises a combination of ascorbic acid and a pharmaceutically acceptable salt of ascorbate... The complaint alleges that administering the Zydus ANDA product, which is alleged to have the claimed formulation, will constitute infringement. ¶55 col. 2:59-63
wherein the pharmaceutical composition comprises less than 0.3% impurities formed by oxidative degradation. The complaint alleges that the administered Zydus ANDA product will meet this stability characteristic. ¶55 col. 8:66-67
  • Identified Points of Contention:
    • Factual Scope Question: The central issue in this ANDA litigation will be whether the specific formulation detailed in Zydus's confidential ANDA submission falls within the scope of the claims. The analysis will depend entirely on a comparison of the ANDA's contents to the claim limitations.
    • Negative Limitation Question: A key technical question may be whether Zydus's product meets the limitation of "less than 0.3% impurities formed by oxidative degradation." The court may need to consider the conditions under which this impurity level is measured and whether the claim is definite.

V. Key Claim Terms for Construction

  • The Term: "a combination of ascorbic acid and a pharmaceutically acceptable salt of ascorbate"
    • Context and Importance: This term defines the core antioxidant system. Its construction is critical because Zydus could argue its product uses a different antioxidant system (e.g., only one of the two components, a different salt, or a different ratio that functions differently) to design around the claim.
    • Evidence for a Broader Interpretation: The claim language "a combination of" does not specify ratios or manufacturing methods, suggesting that the mere presence of both components in the final formulation could suffice. The specification also discusses the components generally ’064 Patent, col. 2:59-63
    • Evidence for a Narrower Interpretation: Defendant may argue that the term implies a synergistic or functionally distinct effect that is only achieved within certain parameters demonstrated in the patent's examples. The patent's reliance on data showing the effect of the antioxidant ’064 Patent, FIG. 1 could be used to argue that "combination" requires achieving that specific result.
  • The Term: "less than 0.3% impurities formed by oxidative degradation"
    • Context and Importance: This is a functional, negative limitation defining the product's performance. Practitioners may focus on this term because its interpretation determines the standard for infringement. A dispute could arise over the methodology, timing, and conditions (e.g., storage temperature, duration) required to measure this impurity level.
    • Evidence for a Broader Interpretation: Plaintiff may argue the plain language sets a clear, objective ceiling on impurities that the accused product must satisfy, regardless of specific testing protocols not mentioned in the claim itself ’064 Patent, claim 1
    • Evidence for a Narrower Interpretation: Defendant may argue the term is indefinite if the conditions for measurement are not sufficiently described. Alternatively, Defendant may point to the stability testing disclosed in the specification (e.g., "at 40° C./75% RH") and argue that the claim scope is implicitly limited to performance under those or similar accelerated testing conditions ’064 Patent, FIG. 1

VI. Other Allegations

  • Indirect Infringement: The complaint alleges both induced and contributory infringement for both patents. The inducement theory is based on the allegation that Zydus's proposed product labeling will instruct and encourage physicians and patients to administer the drug in a way that directly infringes the claims (Compl. ¶¶45, 57). The contributory infringement allegation is based on the assertion that Zydus's product is especially adapted for an infringing use and has no substantial non-infringing use (Compl. ¶¶46, 58).
  • Willful Infringement: The complaint does not use the term "willful," but it alleges that Zydus has had knowledge of the patents since at least the date of its "NDA submission" (Compl. ¶¶47, 59). It further pleads that the case is "exceptional" and seeks attorneys' fees pursuant to 35 U.S.C. § 285 (Compl. ¶¶49, 61).

VII. Analyst’s Conclusion: Key Questions for the Case

The resolution of this case will likely depend on the answers to a few central questions:

  • A core issue will be one of factual formulation: Does the precise chemical composition disclosed in Zydus’s confidential ANDA filing contain every element of the asserted composition claims, including the specific "combination" of antioxidants in the claimed amounts?
  • A key evidentiary question will be one of performance metrics: Does Zydus's proposed generic product, when produced, meet the claimed stability requirement of "less than 0.3% impurities formed by oxidative degradation," and what are the appropriate conditions and methods for making that determination?
  • Finally, for the method patent, a critical question will be one of inducement: Assuming the composition infringes, does the proposed labeling for Zydus's product provide sufficient instruction and encouragement to prescribers and patients to use the drug for treating eosinophilic esophagitis, thereby satisfying the requirements for induced infringement?